Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

TERT, BRAF, and NRAS mutational heterogeneity between paired primary and metastatic melanoma tumors.

Chang GA, Wiggins JM, Corless BC, Syeda MM, Tadepalli JS, Blake S, Fleming N, Darvishian F, Pavlick A, Berman R, Shapiro R, Shao Y, Karlin-Neumann G, Spittle C, Osman I, Polsky D.

J Invest Dermatol. 2020 Feb 19. pii: S0022-202X(20)30159-7. doi: 10.1016/j.jid.2020.01.027. [Epub ahead of print]

PMID:
32087194
2.

Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis.

Efuni E, Cytryn S, Boland P, Niewold TB, Pavlick A, Weber J, Sandigursky S.

J Clin Rheumatol. 2020 Jan 22. doi: 10.1097/RHU.0000000000001314. [Epub ahead of print]

PMID:
31977647
3.

Melanoma Prognosis - Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.

Bajaj S, Donnelly D, Call M, Johannet P, Moran U, Polsky D, Shapiro R, Berman R, Pavlick A, Weber J, Zhong J, Osman I.

J Natl Cancer Inst. 2020 Jan 24. pii: djaa008. doi: 10.1093/jnci/djaa008. [Epub ahead of print]

PMID:
31977051
4.

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.

Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA.

Clin Cancer Res. 2020 Jan 1;26(1):46-53. doi: 10.1158/1078-0432.CCR-18-4180. Epub 2019 Nov 15.

5.

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.

Pavlick A, Blazquez AB, Meseck M, Lattanzi M, Ott PA, Marron TU, Holman RM, Mandeli J, Salazar AM, McClain CB, Gimenez G, Balan S, Gnjatic S, Sabado RL, Bhardwaj N.

Cancer Immunol Res. 2020 Jan;8(1):70-80. doi: 10.1158/2326-6066.CIR-19-0545. Epub 2019 Nov 7.

PMID:
31699709
6.

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.

Rimawi MF, Niravath P, Wang T, Rexer BN, Forero A, Wolff AC, Nanda R, Storniolo AM, Krop I, Goetz MP, Nangia JR, Jiralerspong S, Pavlick A, Veeraraghavan J, De Angelis C, Gutierrez C, Schiff R, Hilsenbeck SG, Osborne CK; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2020 Feb 15;26(4):821-827. doi: 10.1158/1078-0432.CCR-19-0851. Epub 2019 Oct 29.

PMID:
31662331
7.

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy.

De Angelis C, Nagi C, Hoyt CC, Liu L, Roman K, Wang C, Zheng Y, Veeraraghavan J, Sethunath V, Nuciforo P, Wang T, Tsimelzon A, Mao S, Hilsenbeck SG, Trivedi MV, Cataldo ML, Pavlick A, Wolff AC, Weigelt B, Reis-Filho JS, Prat A, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Clin Cancer Res. 2020 Feb 1;26(3):738-745. doi: 10.1158/1078-0432.CCR-19-1402. Epub 2019 Oct 25.

PMID:
31653641
8.

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients.

Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, Weber JS, Osman I, Ahn J.

Genome Med. 2019 Oct 9;11(1):61. doi: 10.1186/s13073-019-0672-4.

9.

The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients.

Donnelly D, Bajaj S, Yu J, Hsu M, Balar A, Pavlick A, Weber J, Osman I, Zhong J.

J Immunother Cancer. 2019 Aug 19;7(1):222. doi: 10.1186/s40425-019-0699-5.

10.

Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM).

Ferguson R, Archambault A, Simpson D, Morales L, Chat V, Kazlow E, Lax R, Yoon G, Moran U, Shapiro R, Pavlick A, Polsky D, Osman I, Kirchhoff T.

Sci Rep. 2019 Jul 15;9(1):10173. doi: 10.1038/s41598-019-46665-z.

11.

Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.

Niravath P, Hilsenbeck SG, Wang T, Jiralerspong S, Nangia J, Pavlick A, Ademuyiwa F, Frith A, Ma C, Park H, Rigden C, Suresh R, Ellis M, Kent Osborne C, Rimawi MF.

Breast Cancer Res Treat. 2019 Sep;177(2):427-435. doi: 10.1007/s10549-019-05319-4. Epub 2019 Jun 19.

PMID:
31218477
12.

Gamma Knife Radiosurgery and Immunotherapy as Primary Treatment for a Malignant Tumor of the Cranial Base Beginning as Lentigo Maligna: A Case Report.

Mureb M, Benjamin C, Sen C, Spino M, Krasnozhen-Ratush O, Zagzag D, Pavlick AC, Kondziolka D.

Pract Radiat Oncol. 2019 Nov;9(6):e608-e612. doi: 10.1016/j.prro.2019.05.010. Epub 2019 May 23. No abstract available.

PMID:
31129314
13.

Frontline Therapy for BRAF-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?

Pavlick AC, Fecher L, Ascierto PA, Sullivan RJ.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:564-571. doi: 10.1200/EDBK_243071. Epub 2019 May 17. Review.

14.

HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2020 Jan 1;112(1):46-54. doi: 10.1093/jnci/djz042.

PMID:
31037288
15.

Impact of initial stage on metastatic melanoma survival.

Wilson MA, Zhong J, Rosenbaum BE, Utter K, Moran U, Darvishian F, Polsky D, Berman RS, Shapiro RL, Pavlick AC, Osman I.

Melanoma Res. 2019 Jun;29(3):281-288. doi: 10.1097/CMR.0000000000000526.

PMID:
31026246
16.

Ipsilateral metastatic choroidal melanoma responds to systemic immunotherapy.

Morkos M, Jain P, Pavlick AC, Finger PT.

Eur J Ophthalmol. 2019 Apr 4:1120672119839925. doi: 10.1177/1120672119839925. [Epub ahead of print]

PMID:
30943789
17.

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.

Finger PT, Pavlick AC.

J Immunother Cancer. 2019 Mar 25;7(1):83. doi: 10.1186/s40425-019-0555-7.

18.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Ann Oncol. 2019 Jun 1;30(6):927-933. doi: 10.1093/annonc/mdz076.

PMID:
30903140
19.

Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition.

Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T.

Cancer Immunol Immunother. 2019 Jun;68(6):897-905. doi: 10.1007/s00262-019-02318-8. Epub 2019 Mar 12.

PMID:
30863922
20.

Revolutionizing treatment of advanced melanoma with immunotherapy.

Carreau N, Pavlick A.

Surg Oncol. 2019 Jan 12. pii: S0960-7404(18)30482-1. doi: 10.1016/j.suronc.2019.01.002. [Epub ahead of print] Review.

PMID:
30691991
21.

A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.

Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O.

Cancer. 2019 Apr 1;125(7):1113-1123. doi: 10.1002/cncr.31892. Epub 2019 Jan 28.

22.

Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma.

Carreau NA, Pavlick AC.

Future Oncol. 2019 Feb;15(4):349-358. doi: 10.2217/fon-2018-0607. Epub 2018 Oct 18. Review.

PMID:
30334646
23.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

24.

MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.

Rodig SJ, Gusenleitner D, Jackson DG, Gjini E, Giobbie-Hurder A, Jin C, Chang H, Lovitch SB, Horak C, Weber JS, Weirather JL, Wolchok JD, Postow MA, Pavlick AC, Chesney J, Hodi FS.

Sci Transl Med. 2018 Jul 18;10(450). pii: eaar3342. doi: 10.1126/scitranslmed.aar3342.

PMID:
30021886
25.

Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.

Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, Hernando E, Polsky D, Hanniford D, Shapiro R, Berman R, Pavlick AC, Wilson MA, Kirchhoff T, Weber JS, Zhong J, Osman I.

J Natl Cancer Inst. 2019 Feb 1;111(2):180-188. doi: 10.1093/jnci/djy086.

PMID:
29912415
26.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

27.

Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.

Lattanzi M, Han J, Moran U, Utter K, Tchack J, Sabado RL, Berman R, Shapiro R, Huang HH, Osman I, Bhardwaj N, Pavlick AC.

J Immunother Cancer. 2018 May 18;6(1):38. doi: 10.1186/s40425-018-0345-7.

28.

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.

Gowen MF, Giles KM, Simpson D, Tchack J, Zhou H, Moran U, Dawood Z, Pavlick AC, Hu S, Wilson MA, Zhong H, Krogsgaard M, Kirchhoff T, Osman I.

J Transl Med. 2018 Apr 2;16(1):82. doi: 10.1186/s12967-018-1452-4.

29.

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma.

D'Angelo SP, Hamid OA, Tarhini A, Schadendorf D, Chmielowski B, Collichio FA, Pavlick AC, Lewis KD, Weil SC, Heyburn J, Schweizer C, O'Shannessy DJ, Carvajal RD.

Invest New Drugs. 2018 Feb;36(1):103-113. doi: 10.1007/s10637-017-0530-4. Epub 2017 Nov 11.

PMID:
29127533
30.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

31.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.

32.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Gangadhar TC, Hwu WJ, Postow MA, Hamid O, Daud A, Dronca R, Joseph R, O'Day SJ, Hodi FS, Pavlick AC, Kluger H, Oxborough RP, Yang A, Gazdoiu M, Kush DA, Ebbinghaus S, Salama AKS.

J Immunother. 2017 Nov/Dec;40(9):334-340. doi: 10.1097/CJI.0000000000000186.

33.

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Hamid O, Puzanov I, Dummer R, Schachter J, Daud A, Schadendorf D, Blank C, Cranmer LD, Robert C, Pavlick AC, Gonzalez R, Hodi FS, Ascierto PA, Salama AKS, Margolin KA, Gangadhar TC, Wei Z, Ebbinghaus S, Ibrahim N, Ribas A.

Eur J Cancer. 2017 Nov;86:37-45. doi: 10.1016/j.ejca.2017.07.022.

PMID:
28961465
34.

Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.

Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I.

Oncology. 2017;93(4):249-258. doi: 10.1159/000478050. Epub 2017 Jul 27. Review.

35.

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management.

Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C.

Cancer Treat Rev. 2017 Jul;58:70-76. doi: 10.1016/j.ctrv.2017.06.002. Epub 2017 Jun 22. Review.

36.

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.

Goldman C, Tchack J, Robinson EM, Han SW, Moran U, Polsky D, Berman RS, Shapiro RL, Ott PA, Osman I, Zhong H, Pavlick AC, Wilson MA.

Oncology. 2017;93(3):164-176. doi: 10.1159/000475715. Epub 2017 Jun 10.

PMID:
28601879
37.

Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma.

Raad RA, Kannan R, Madden K, Pavlick A.

Clin Nucl Med. 2017 Jul;42(7):e345-e346. doi: 10.1097/RLU.0000000000001673.

PMID:
28481788
38.

Toward the complete control of brain metastases using surveillance screening and stereotactic radiosurgery.

Wolf A, Kvint S, Chachoua A, Pavlick A, Wilson M, Donahue B, Golfinos JG, Silverman J, Kondziolka D.

J Neurosurg. 2018 Jan;128(1):23-31. doi: 10.3171/2016.10.JNS161036. Epub 2017 Feb 17.

PMID:
28298015
39.

Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab.

Stevenson ML, Wang CQ, Abikhair M, Roudiani N, Felsen D, Krueger JG, Pavlick AC, Carucci JA.

JAMA Dermatol. 2017 Apr 1;153(4):299-303. doi: 10.1001/jamadermatol.2016.5118.

PMID:
28259107
40.

MAGEA3 Expression in Cutaneous Squamous Cell Carcinoma Is Associated with Advanced Tumor Stage and Poor Prognosis.

Abikhair M, Roudiani N, Mitsui H, Krueger JG, Pavlick A, Lee J, Therrien JP, Meehan SA, Felsen D, Carucci JA.

J Invest Dermatol. 2017 Mar;137(3):775-778. doi: 10.1016/j.jid.2016.10.036. Epub 2016 Nov 5. No abstract available.

41.

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors.

Adjei AA, LoRusso P, Ribas A, Sosman JA, Pavlick A, Dy GK, Zhou X, Gangolli E, Kneissl M, Faucette S, Neuwirth R, Bózon V.

Invest New Drugs. 2017 Feb;35(1):47-58. doi: 10.1007/s10637-016-0391-2. Epub 2016 Sep 21.

42.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.

Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.

43.

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

Leijen S, van Geel RM, Pavlick AC, Tibes R, Rosen L, Razak AR, Lam R, Demuth T, Rose S, Lee MA, Freshwater T, Shumway S, Liang LW, Oza AM, Schellens JH, Shapiro GI.

J Clin Oncol. 2016 Dec 20;34(36):4371-4380. doi: 10.1200/JCO.2016.67.5991. Epub 2016 Oct 31.

PMID:
27601554
44.

Metastatic Cutaneous Squamous Cell Carcinoma: The Importance of T2 Stratification and Hematologic Malignancy in Prognostication.

Stevenson ML, Kim R, Meehan SA, Pavlick AC, Carucci JA.

Dermatol Surg. 2016 Aug;42(8):932-5. doi: 10.1097/DSS.0000000000000798.

PMID:
27467226
45.

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.

Bhatia S, Pavlick AC, Boasberg P, Thompson JA, Mulligan G, Pickard MD, Faessel H, Dezube BJ, Hamid O.

Invest New Drugs. 2016 Aug;34(4):439-49. doi: 10.1007/s10637-016-0348-5. Epub 2016 Apr 8.

46.

Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases.

Wolf A, Zia S, Verma R, Pavlick A, Wilson M, Golfinos JG, Silverman JS, Kondziolka D.

J Neurooncol. 2016 May;127(3):607-15. doi: 10.1007/s11060-016-2072-6. Epub 2016 Feb 6.

PMID:
26852222
47.

Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.

Silva IP, Salhi A, Giles KM, Vogelsang M, Han SW, Ismaili N, Lui KP, Robinson EM, Wilson MA, Shapiro RL, Pavlick A, Zhong J, Kirchhoff T, Osman I.

Clin Cancer Res. 2016 May 15;22(10):2377-85. doi: 10.1158/1078-0432.CCR-15-1811. Epub 2015 Dec 2.

48.

Somatic and germline analyses of a long term melanoma survivor with a recurrent brain metastasis.

Weiss S, Darvishian F, Tadepalli J, Shapiro R, Golfinos J, Pavlick A, Polsky D, Kirchhoff T, Osman I.

BMC Cancer. 2015 Nov 23;15:926. doi: 10.1186/s12885-015-1927-0.

49.

Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.

Chang GA, Tadepalli JS, Shao Y, Zhang Y, Weiss S, Robinson E, Spittle C, Furtado M, Shelton DN, Karlin-Neumann G, Pavlick A, Osman I, Polsky D.

Mol Oncol. 2016 Jan;10(1):157-65. doi: 10.1016/j.molonc.2015.09.005. Epub 2015 Sep 25.

50.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796

Supplemental Content

Loading ...
Support Center